TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05961020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total body vibration
Description: Whole-body vibration (WBV) training has been established as a useful method to improve physical fitness in obese individuals. Vibration stimulus during half squatting might suggest a long-term effect of WBV on the endocrine system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate restricted diet
Description: moderate restricted diet
Study: NCT05125029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
Study: NCT06280378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL003 Cell Injection Drug Product
Description: Administered by intravenous infusion after myeloablative conditioning with busulfan.
Study: NCT06434922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevention Strategies
Description: Data collection sessions lasted approximately 1 to 1.50 hours, with education and foot care provided once a month. Subsequently, patients underwent monthly follow-ups for three months, during which they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Strategiies
Description: Group were educated about DM management, medication adherence, dietary practices, physical exercise routines, and foot care through pamphlets
Study: NCT06209814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary open-faced denture
Description: Patients in this group received a maxillary open faced denture with soft acryl resin wing and a conventional mandibular complete denture. The patients used these dentures for 45 days. Afterward, the maxillary open-faced denture was replaced by one with a conventional construction.
Study: NCT05738707

Intervention type: BIOLOGICAL
Intervention: Recombinant protein vaccine and adenovirus vector vaccine
Description: Administer recombinant protein vaccine and adenovirus vector vaccine

Intervention type: BIOLOGICAL
Intervention: Recombinant protein vaccine and adenovirus vector vaccine
Description: Administer recombinant protein vaccine and adenovirus vector vaccine
Study: NCT05260359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation
Description: SU E 101413 85

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation
Description: SU E 101413 85

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol (BEMT) dispersion in petrolatum
Description: SU-E-101413-82

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol (BEMT) dispersion in petrolatum
Description: SU-E-101413-82

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT
Description: SU E 101413 91

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT
Description: SU E 101413 91

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum vehicle
Description: SU-E-101413-83

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum vehicle
Description: SU-E-101413-83

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: low irritancy control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: low irritancy control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Lauryl Sulfate 0.1% (SLS)
Description: positive control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Undosed patch
Description: negative control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Undosed patch
Description: negative control
Study: NCT06252766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiment (Clown)
Description: Children included in the intervention group will be accompanied by a clown at the door from the moment they enter the intervention room and The child will be made to sit on the blood collection chair by playing games with them. Meanwhile, the nurse will take blood from the child. lasts for about 2-3 minutes. During this process, the clown is constantly playing games and foam will continue to distract you by blowing up balloons. The child's pain and anxiety score during the procedure the researcher will be evaluated by both the parent and the child. After the procedure is finished, the children will be will be taken out of the room and taken to the waiting area in the next room. Afterwards, the children will be asked how much pain and anxiety they felt during the blood collection procedure. After being allowed to rest for 1-2 minutes a questionnaire form will be applied to the children.
Study: NCT05001061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Pill
Description: sublingual versus vaginal Misoprostol in termination of first trimester missed abortion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Pill
Description: sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
Study: NCT04819802

Intervention type: OTHER
Intervention: Measurement of sublingual microcirculation
Description: Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.

Intervention type: OTHER
Intervention: Plasma sampling
Description: Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.
Study: NCT06520332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Surgery - short implant group (less than or equal to 6mm)
Description: A mucoperiosteal flap will be raised in edentulous ridge. A short dental implant (experimental group) will be placed according to the standard protocol.~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant Surgery - Conventional implant group (greater than or equal to 10mm)
Description: A mucoperiosteal flap will be raised in edentulous ridge. A standard length implant ( comparative group) ( ≥10mm) will be placed according to the standard protocol in the augmented/native bone .~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures
Study: NCT06366399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Timing
Description: 1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Timing
Description: 1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
Study: NCT05940623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care and home IOP telemonitoring with smart phone-based intervention
Description: We expect that (1) GAT measurements over 30 months of follow-up for patients randomized to Management Paradigm I to be smaller compared with those randomized to Management Paradigm II; and that (2) the rates of RNFL/GCIPL thinning would be slower for those randomized to Management Paradigm I compared with those randomized to Management Paradigm II
Study: NCT06213467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser 940nm
Description: Exposure for the two implants was done at the same visit, with one implant being exposed using diode laser and the other implant using traditional method
Study: NCT05457049

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular residual disease test
Description: OncoMRD Lung
Study: NCT05702775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment group (EUS-GBD group
Description: The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
Study: NCT04406792

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP only
Description: Participation in the online DPP only with a mixed group of participants at risk for type 2 diabetes and doula divas are not the team leaders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP) online + doula divas
Description: Participation in the DPP online intervention with doula divas as team leaders.
Study: NCT05327049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: treatment of deep carious lesions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: laser light for cavity disinfection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Vera
Description: herbal dietary supplement for treatment of deep carious lesions
Study: NCT04810260

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use mobile health app (WellXcel) to increase knowledge
Description: Download the app (WellXcel) to the mobile device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use mobile health app (WellXcel) to increase knowledge
Description: Download the app (WellXcel) to the mobile device
Study: NCT05896774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept
Description: Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
Study: NCT05664334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121 without MF59®
Study: NCT06104241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGT007 Injection
Description: BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.
Study: NCT04952077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging (MRI)
Study: NCT05142098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Description: Orally
Study: NCT06233084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel-Test product
Description: Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel-Reference product
Description: Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
Study: NCT05040646

Intervention type: OTHER
Intervention: Delphi exercise
Description: During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached.

Intervention type: OTHER
Intervention: Delphi exercise
Description: During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached.
Study: NCT05038696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
Study: NCT05007314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biocriminological Evidence
Description: Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biocriminological Evidence
Description: Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
Study: NCT06133075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG
Description: 10 patients will receive drug for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 25 MG
Description: 10 patients will receive drug for 8 weeks
Study: NCT04860050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmipure Gold®
Description: TPG: Turmipure GOLD® - 1 capsule per day - as prescribed

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: colored acacia gum - 1 capsule per day - as prescribed
Study: NCT05097417

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine and ablation in the primary tumor sites
Description: Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
Study: NCT05664334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 75 mcg of IVX-241 without MF59®

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent
Study: NCT05097417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: Patients will be treated with ablation in the primary tumor sites
Study: NCT05664334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121, without MF59®
Study: NCT05504512

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05531500

Intervention type: DRUG
Group type: OTHER
Intervention: Injection
Description: Injection of local anesthetic + steroids

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency
Description: Application of radiofrequency on the diseased nerve
Study: NCT05664334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121, without MF59®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 150 mcg IVX-241, without MF59®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 225 mcg of IVX-241, without MF59®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121, with MF59®
Study: NCT06322043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipearl
Description: Injection of the investigational device in subcutaneous tissue.
Study: NCT05664334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-121
Description: 75 mcg of IVX-121, with MF59®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 75 mcg of IVX-241, with MF59®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-241
Description: 150 mcg IVX-241, with MF59®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59®
Description: MF59® as an adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59®
Description: MF59® as an adjuvant
Study: NCT06177444

Intervention type: DRUG
Intervention: Antibiotic
Description: Postoperative antibiotic treatment
Study: NCT05633719

Intervention type: OTHER
Intervention: Chemotherapy involving cisplatin or carboplatin
Description: Chemotherapy
Study: NCT06522958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dissolving Transitional Food
Description: Transitional foods are solid foods that rapidly change texture in the presence of moisture (e.g., water or saliva) or temperature change. Duration of consumption of the investigational agent will include the time of the surgery until the second post-operative evaluation. This is estimated to be approximately 1-2 months in total.
Study: NCT06397144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxlovid
Description: Reference 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxlovid
Description: Reference 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Test 2
Study: NCT05464316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Transobturator Male System
Description: The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Urinary Sphincter
Description: The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter.
Study: NCT06411743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Albumin Injection
Description: Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Albumin Injection
Description: Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin
Description: Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin
Description: Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
Study: NCT05861193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of the abfraction with BOPT technique
Description: The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~* Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~* Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~* Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~* Removal of the retraction cord.~* Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~* Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry.
Study: NCT06133049

Intervention type: DRUG
Intervention: Ozanimod
Description: Women with MS who were exposed to ozanimod during pregnancy

Intervention type: DRUG
Intervention: Select DMTs other than ozanimod
Description: Women with MS exposed to select DMTs other than ozanimod during pregnancy

Intervention type: DRUG
Intervention: No DMTs
Description: Women with MS not exposed to any DMTs during pregnancy
Study: NCT06303492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GUS
Description: Aspiration risk assessment by GUS
Study: NCT05368831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-1024
Description: Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
Study: NCT05330234

Intervention type: DEVICE
Group type: OTHER
Intervention: OnTrack Tools
Description: The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management.